PT  - JOURNAL ARTICLE
AU  - Buturovic, Ljubomir
AU  - Zheng, Hong
AU  - Tang, Benjamin
AU  - Lai, Kevin
AU  - Kuan, Win Sen
AU  - Gillett, Mark
AU  - Santram, Rahul
AU  - Shojaei, Maryam
AU  - Almansa, Raquel
AU  - Ángel Nieto, Jose
AU  - Muñoz, Sonsoles
AU  - Herrero, Carmen
AU  - Antonakos, Nikolaos
AU  - Koufargyris, Panayiotis
AU  - Kontogiorgi, Marina
AU  - Damoraki, Georgia
AU  - Liesenfeld, Oliver
AU  - Wacker, James
AU  - Midic, Uros
AU  - Luethy, Roland
AU  - Rawling, David
AU  - Remmel, Melissa
AU  - Coyle, Sabrina
AU  - Liu, Yiran E.
AU  - Rao, Aditya M
AU  - Dermadi, Denis
AU  - Toh, Jiaying
AU  - Jones, Lara Murphy
AU  - Donato, Michele
AU  - Khatri, Purvesh
AU  - Giamarellos-Bourboulis, Evangelos J.
AU  - Sweeney, Timothy E
TI  - A 6-mRNA host response whole-blood classifier trained on pre-pandemic data accurately predicts severity in COVID-19 and other acute viral infections
AID  - 10.1101/2020.12.07.20230235
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.07.20230235
4099  - http://medrxiv.org/content/early/2021/05/02/2020.12.07.20230235.short
4100  - http://medrxiv.org/content/early/2021/05/02/2020.12.07.20230235.full
AB  - Background Determining the severity of COVID-19 remains an unmet medical need. Our objective was to develop a blood-based host-gene-expression classifier for the severity of viral infections and validate it in independent data, including COVID-19.Methods We developed the classifier for the severity of viral infections and validated it in multiple viral infection settings including COVID-19. We used training data (N=705) from 21 retrospective transcriptomic clinical studies of influenza and other viral illnesses looking at a preselected panel of host immune response messenger RNAs.Results We selected 6 host RNAs and trained logistic regression classifier with a cross-validation area under curve of 0.90 for predicting 30-day mortality in viral illnesses. Next, in 1,417 samples across 21 independent retrospective cohorts the locked 6-RNA classifier had an area under curve of 0.91 for discriminating patients with severe vs. non-severe infection. Next, in independent cohorts of prospectively (N=97) and retrospectively (N=100) enrolled patients with confirmed COVID-19, the classifier had an area under curve of 0.89 and 0.87, respectively, for identifying patients with severe respiratory failure or 30-day mortality. Finally, we developed a loop-mediated isothermal gene expression assay for the 6-messenger-RNA panel to facilitate implementation as a rapid assay.Conclusions With further study, the classifier could assist in the risk assessment of COVID-19 and other acute viral infections patients to determine severity and level of care, thereby improving patient management and reducing healthcare burden.Competing Interest StatementLB, OL, JW, UM, RL, DR, MR, SC, and TES are employees of, and stockholders in, Inflammatix, Inc, which is developing the 6-mRNA score into a commercial assay, CoVerityTM. PK is a shareholder and a consultant to Inflammatix, Inc. EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMerieux Inc, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie- Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors declare no competing interests. Clinical TrialEudraCT 2020-001039-29Funding StatementThis study was funded by Inflammatix Inc. No external funding was received Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COVID-19 blood samples were collected between March and April 2020. The studies were conducted following approvals for the collection of biomaterial for transcriptomic analysis for patients with lower respiratory tract infections provided by the Ethics Committees of the participating hospitals. The studies were conducted under the 23/12.08.2019 approval of the Ethics Committee of Sotiria Athens General Hospital; and the 26.02.2019 approval of the Ethics Committee of ATTIKON University General Hospital. Written informed consent was provided by patients or by first-degree relatives in case of patients unable to consent. For Australia/WIMR study, the written consent is provided by all patients or by first-degree relatives in case of patients unable to consent. The study was approved by the human research ethics committee of the Nepean Blue Mountains Area Health Services. For PREVISE study, the IRB was approved by COMITE DE ETICA DE LA INVESTIGACION CON MEDICAMENTOS DEL AREA DE SALUD DE SALAMANCA, Paseo de San Vicente, 58-18, 237007 Salamanca, Spain For healthy commercial controls, blood RNA tubes were prospectively collected from healthy controls (HC) through a commercial vendor (BioIVT) under IRB approval (Western IRB #2016165) using informed consent. Stanford ICU databank and PROMPT studies have previously been published and provided IRB details.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe public cohorts are available under their respective study IDs. The Stanford ICU Databank study is available at https://doi.org/10.1038/s41467-020-14975-w. The COVID-19 NanoString data are available upon reasonable request from the authors. https://doi.org/10.1038/s41467-020-14975-w